Drug-resistant tuberculosis medical therapy: Difference between revisions

Jump to navigation Jump to search
Line 59: Line 59:
|-
|-


| style="font-size: 90%; padding: 0 5px; background: #F5F5F5;" align=left |<small>Table adapted from WHO 2013 Treatment of tuberculosis: guidelines – 4th ed.<ref name="WHO 2013"> {{Cite web| url= http://www.who.int/tb/publications/tb_treatmentguidelines/en/| Title= 2013 WHO Treatment of Tuberculosis: Guidelines for National Programmes (4th Edition}}</ref></small>
| style="font-size: 90%; padding: 0 5px; background: #F5F5F5;" align=left |<small>Table adapted from WHO 2013 Treatment of tuberculosis: guidelines – 4th ed.<ref name="WHO 2013"> {{Cite web| url=http://www.who.int/tb/publications/tb_treatmentguidelines/en/| Title=2013 WHO Treatment of Tuberculosis: Guidelines for National Programmes (4th Edition}}</ref></small>


|}
|}

Revision as of 15:40, 17 September 2014

Tuberculosis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Tuberculosis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Children

HIV Coinfection

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Special Conditions
Drug-resistant

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Drug-resistant tuberculosis medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Drug-resistant tuberculosis medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Drug-resistant tuberculosis medical therapy

CDC on Drug-resistant tuberculosis medical therapy

Drug-resistant tuberculosis medical therapy in the news

Blogs on Drug-resistant tuberculosis medical therapy

Directions to Hospitals Treating Tuberculosis

Risk calculators and risk factors for Drug-resistant tuberculosis medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Alejandro Lemor, M.D. [2]

Overview

Multiple Drug-Resistant (MDR) Tuberculosis

  • MDR-TB is defined as resistance to isoniazid and rifampicin, with or without resistance to other first-line drugs.
  • Medical treatment for MDR-TB consists of at least 4 drugs that have shown effectiveness against MDR.
  • Treatment duration will depend on the culture results. The duration of therapy should be > 18 months after culture is negative.
  • Chronic cases with severe pulmonary disease may require more than 24 months of therapy.

MDR Tuberculosis

  ▸  Adults

  ▸  Children

MDR-TB Adults
Standard Regimen
Group 1: First-line oral drugs

Pyrazinamide
OR
Ethambutol
OR
Rifabutin

PLUS
Group 2: Injectable drugs

Kanamycin
OR
Amikacin
OR
Capreomycin
OR
Streptomycin

PLUS
Group 3: Fluoroquinolones

Levofloxacin
OR
Moxifloxacin
OR
Ofloxacin

PLUS
Group 4:Oral bacteriostatic second-line drugs

Para-aminosalicylic acid
OR
Cycloserine
OR
Terizidone
OR
Ethionamide
OR
Protionamide

Table adapted from WHO 2013 Treatment of tuberculosis: guidelines – 4th ed.[1]
MDR-TB Children
Preferred Regimen

Extensively Drug-Resistant XDR Tuberculosis

XDR-TB is defined as resistance to at least isoniazid and rifampicin, and to any fluoroquinolone, and to any of the three second-line injectables (amikacin, capreomycin, and kanamycin).

XDR Tuberculosis

  ▸  Adults

  ▸  Children

XDR-TB Adults
Preferred Regimen
▸ '
XDR-TB Children
Preferred Regimen

Extremely Drug-Resistant (XXDR) Tuberculosis

References

  1. http://www.who.int/tb/publications/tb_treatmentguidelines/en/. Unknown parameter |Title= ignored (|title= suggested) (help); Missing or empty |title= (help)